Here's a fun finance puzzle for you: a company reports quarterly earnings that beat expectations, then immediately lowers its full-year guidance. What happens to the stock? If you guessed "it goes down," you'd be wrong—at least in the case of Boston Scientific Corporation (BSX) on Wednesday.
The medical technology giant posted first-quarter 2026 revenues of $5.20 billion, slightly better than the consensus estimate of $5.17 billion. That's up 11.6% on a reported basis, landing within the company's guidance range of 10.5%-12%. On an operational and organic basis, sales grew 9.4%, also within the expected band of 8.5%-10%.
Adjusted earnings came in at 80 cents per share, beating both the consensus of 79 cents and the management's own guidance range of 78-80 cents. So far, so good—a clean beat on the top and bottom lines. But then the guidance part happened.
The Cardiovascular Engine
The revenue growth was driven primarily by a strong performance in the Cardiovascular segment, which is basically Boston Scientific's main business engine. This segment generated $3.503 billion in revenue with 11% organic growth. Let's break that down, because the details matter.
Within Cardiovascular, Electrophysiology brought in $905 million, up 22%. Watchman—that's the left atrial appendage closure device—generated $506 million, up 19%. Interventional Cardiology & Vascular Therapies delivered $1.24 billion, up 8%. Interventional Oncology & Embolization added $268 million, up 15%. The only weak spot was Cardiac Rhythm Management, which declined 3% to $578 million.
The MedSurg segment delivered $1.70 billion, up 6%, with Neuromodulation growing 15% to $318 million and Endoscopy up 7% to $736 million. Urology grew modestly at 1% to $646 million.
The Guidance Cut
Now, here's where it gets interesting. After reporting these solid numbers, Boston Scientific lowered its fiscal 2026 adjusted earnings per share guidance from $3.43-$3.49 to $3.34-$3.41. That's below the Wall Street estimate of $3.45.
The company also forecasts net sales growth of approximately 7%-8.5% on a reported basis for the full year, down from prior guidance of 10.5%-11.5%. On an organic basis, growth is now expected to be 6.5%-8%, down from 10%-11%. In dollar terms, that translates to 2026 sales guidance of $21.48 billion-$21.78 billion, lowered from $22.18 billion-$22.38 billion and below the consensus of $22.23 billion.
So to recap: great quarter, weaker full-year outlook. Normally, that combination would make investors nervous. But Boston Scientific shares were up 8.67% at $64.68 at the time of publication on Wednesday, according to market data.
Why the Rally?
There are a few ways to think about this. One is that the Q1 beat was strong enough to outweigh concerns about the guidance cut. Another is that investors are looking past the near-term pressure and focusing on the underlying business strength, particularly in high-growth areas like Electrophysiology and Watchman.
The company's second-quarter guidance does signal some near-term challenges. Boston Scientific expects net sales growth of approximately 5.5%-7.5% on a reported basis and 5%-7% organically in Q2 2026, equivalent to sales of $5.34 billion-$5.44 billion. That's below the consensus of $5.55 billion. Adjusted earnings are projected at 82-84 cents versus the consensus of 86 cents.
So the market is essentially saying: "We see the Q2 pressure, we see the lowered full-year outlook, but we like what we saw in Q1 enough to look through it." It's a vote of confidence in the company's ability to execute, even in a somewhat softer growth environment.
Sometimes in finance, the immediate reaction to earnings tells you more about investor sentiment than the numbers themselves. In this case, Boston Scientific gave investors a mixed bag—strong quarterly results but reduced future expectations—and the market decided to focus on the good stuff. That's why the stock is soaring on a day when, on paper, the news wasn't all positive.
